Abiomed set to conquer the heart's last frontier
This article was originally published in Clinica
Executive Summary
Abiomed, which is selling temporary heart assist machines and is working on what its CEO, Devid Lederman, calls the "last frontier in cardiac medicine" - the permanent, implantable, artificial heart - is clear about the significance of his company's final goal. Mr Lederman told the BancBoston Robertson Stephens conference earlier this month: "If you can replace the human heart, then a lot of other therapies will become superfluous."